Imperial College London
Alternate

DrLauraKenny

Faculty of Medicine, Department of Surgery & Cancer

Clinical Senior Lecturer in Medical Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2806l.kenny

 
 
//

Location

 

137ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@inproceedings{Howell:2022:10.1158/1538-7445.SABCS21-P1-18-10,
author = {Howell, SJ and Kenny, LM and Lord, S and Krebs, MG and Arkenau, T and Baird, R and MacPherson, IR and Bahl, A and Clack, G and Ainscow, E and Barrett, AGM and Dickinson, PA and Fuchter, MJ and Lehnert, M and Ali, S and McIntosh, S and Coombes, C},
doi = {10.1158/1538-7445.SABCS21-P1-18-10},
publisher = {AMER ASSOC CANCER RESEARCH},
title = {A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)},
url = {http://dx.doi.org/10.1158/1538-7445.SABCS21-P1-18-10},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - CPAPER
AU  - Howell,SJ
AU  - Kenny,LM
AU  - Lord,S
AU  - Krebs,MG
AU  - Arkenau,T
AU  - Baird,R
AU  - MacPherson,IR
AU  - Bahl,A
AU  - Clack,G
AU  - Ainscow,E
AU  - Barrett,AGM
AU  - Dickinson,PA
AU  - Fuchter,MJ
AU  - Lehnert,M
AU  - Ali,S
AU  - McIntosh,S
AU  - Coombes,C
DO  - 10.1158/1538-7445.SABCS21-P1-18-10
PB  - AMER ASSOC CANCER RESEARCH
PY  - 2022///
SN  - 0008-5472
TI  - A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
UR  - http://dx.doi.org/10.1158/1538-7445.SABCS21-P1-18-10
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000772647600276&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
ER  -
Download